ACN Newswire

Genes Tech Group Announces 2024 Interim Results

HONG KONG, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - Genes Tech Group Holdings Co. Ltd (“Genes Tech Group” or “The Group”; Stock Code: 8257.HK) announces its interim results for the six months ended 30 June, 2024 (“the period”). During the period, the Group recorded the total revenue of approximately NTD535.01 million, Total comprehensive income for the period attributable to owners of the Company amounted to approximately NTD31.30 million. Basic earnings per share were NTD3.87 cents.During the period, revenue from turnkey solutions amounted to approximately NTD226.60 million, accounting for approximately 42.35% of the Group’s total revenue. The revenue from trading of parts and used SME amounted to approximately NTD308.41 million, accounting for approximately 57.65% of the Group’s total revenue. During the period under review, under the ongoing geopolitical tensions, the Group deepened cooperation with existing international clients and continually explored new areas and models of collaboration. The Group's revenue from operation in Japan significantly increased by 7,038.01% compared with last year, representing approximately 9.79% of the Group's total revenue, while revenue from operation in the United States increased by 15.54% from last year, representing approximately 23.70% of the Group's total revenue.In the first half of 2024, the rise of generative artificial intelligence (AI) technology has provided significant growth impetus for demand on chips and memory. However, the uncertainties of the global economic environment, along with the slowdown in the growth of the industrial and automotive sectors, leading to a slower-than-expected pace of recovery for the entire semiconductor industry. According to the data recently released by the Semiconductor Industry Association (SIA), the monthly sales of the global semiconductor industry have achieved year-on-year growth since 2024. In May, sales reached USD49.1 billion, with an annual growth rate of 19.3% and a monthly growth rate of 4.1%. Such annual growth rate was the highest since April 2022, showcasing the vigorous development trend of generative AI applications, which brought a strong growth momentum to the semiconductor industry.Mr. Yang Ming-Hsiang, Chairman and Chief Executive Officer concluded: “With the rapid development of AI technology, the market is entering a new era fully empowered by AI. This transformation not only deeply reconstructs industry ecosystems but also opens unprecedented golden opportunities for the semiconductor industry. The robust demand for AI and high-performance computing data centers is driving chip manufacturers to establish closer collaborations with memory, packaging and testing companies, working together to build a strong ecosystem, thus enhancing the overall competitiveness of the entire industry chain. However, the complex geopolitical landscape continues to have profound effects on the global semiconductor industry, especially in AI, which is a core area of Sino-US competition. The Group will adopt a cautious strategy, flexibly adapting to market changes and seizing development opportunities. At the same time, the Group will also strive to achieve breakthroughs in key technologies to solidify our market position in intense competition, aiming to create long-term and sustainable value returns for the shareholders.”About Genes Tech Group Holdings Co Ltd (Stock Code: 8257.HK)Genes Tech Group Holdings Co. Ltd is a turnkey solution provider and exporter of parts and used SME in Taiwan. Since the commencement of its business in 2009, the Group mainly engaged in providing turnkey solution for parts and used SME for its customers and modifying and/or upgrading the semiconductor equipment of its production systems according to customers needs. In addition, the Group is also engaged in the trading of SEM and parts. The SME and parts supplied by the Group included furnaces, clean tracks and other related items, which were used at the front-end of the semiconductor manufacturing process, wafer fabrication such as deposition, photoresist coating and development, and these were extensively applied in mobile phones, game consoles, DVD players, automotive sensors and other digital electronic products. Visit https://www.genestech.com/en/.Press release distributed by Vitalink Consultants for Genes Tech Group Holdings Co. Ltd. For enquiries, please contact:Ms. Natural Lau   T: +852 2529 7999   E: Natural.lau@vitalink.com.hk  Copyright 2024 ACN Newswire via SeaPRwire.com.

SeaPRwire

亚洲公司突破Ac-225制备关键技术

磐美迪国际团队共同努力，完成Ac-225量产核心技术工艺验证 伦敦，2024年8月15日 - (SeaPRwire) - 2024年8月，磐美迪控股(深圳)有限公司在国际团队共同的努力和权威专家的见证下，于英国伦敦发布突破新型医用同位素Ac-225关键性生产技术的消息，该技术同时得到了英国知名研究型大学的严格验证，为磐美迪在Ac-225的规模商业化量产方面又迈进了具有里程碑意义的一步。 磐美迪作为国际领先的医用同位素Ac-225 及Ge-68的研发、生产及销售企业，首阶段致力于解决我国医用同位素长期依赖进口所面临的技术和产能瓶颈等“卡脖子”问题，实现Ac-225 及Ge-68 全流程国产化。 公司团队汇集了多国核医药领域的顶尖技术人才，分别由英国皇家工程院和英国皇家科学院的双院士、英国政府的核燃料专家、加拿大核实验室的前首席科学家，以及清华大学、英国帝国理工大学、香港理工大学、深圳大学、西南医科大学等权威专家和教授组成，专注于放射性同位素和核医药的研究与临床应用。 Ac-225被认为是最具临床应用前景的治疗用医用同位素之一，目前全球已有数十项Ac-225药物管线进入临床研究阶段，覆盖前列腺癌、神经内分泌肿瘤、非小细胞肺癌、乳腺癌以及多种实体瘤等适应症的多数癌种。 Ac-225在临床研究和治疗应用中因其优异的治疗效果，不仅能提高患者的生存率，提高治疗效果，减少治疗副作用，而且有效降低医疗成本，已经成为全球各大药企一致看好并争相布局的最优秀和最有前景的医用同位素之一。而全球Ac-225的生产关键技术仅由国外极少数的几个先进团队掌握，生产工艺需要经过一系列复杂的核反应和分离过程，因此供应极其有限，产能资源长期严重稀缺。而随着国内外相关临床研究与治疗需求的不断增加，这种供需失衡进一步加剧了Ac-225的紧缺性。磐美迪弥补Ac-225的巨大供应缺口，倍受全球瞩目，将有效地支持新癌症治疗方法的进一步探索。该双重价值，进一步体现了磐美迪作为全球健康事业的重要参与者之一，将致力以技术创新、国际合作推动全球健康为宗旨，坚定为实现人类命运共同体而努力的目标。 磐美迪联合创始人、英国董事CEO、Andrew Carlick院士表示：“磐美迪所采用回旋加速器制备的Ac-225 技术十分成熟，已通过机构验证，具有纯度高、产量大、辐射低、原料损耗低等优势。是我们多年来智慧和资源的结晶，在癌症治疗方面发挥显著作用，在国际化团队共同的努力下，将继续推动核医药技术的发展。” 磐美迪联合创始人、中国董事CEO、邓立鸣先生表示:“磐美迪将继续致力于技术和工艺的创新发展，计划未来进一步拓展如Ac-225和Ge-68等医用同位素的应用领域，为放射性药物的开发提供从原料到成品，从研究到放大以及商业化级别生产的全流程解决方案，构建从同位素生产、核心装备研发、核药RXO、新一代诊断设备到AI+TAT的核医药全流程技术体系平台。在加强放射性药物研发力量的同时，推进世界先进技术临床转化与应用，为科学研究和医疗健康贡献磐美迪力量。”     磐美迪控股（深圳）有限公司 公司联络人：Claire Zhao 公司联系方式：pchl@panmedisoholdings.com 公司官网：http://panmedisoholdings.com/

SeaPRwire

An Asian Company Achieves Breakthrough in the Key Technology of Ac-225 Preparation

PanMediso Holdings’ international team completes core technology verification for mass production of Ac-225 London, UK – August 15, 2024 – (SeaPRwire) -PanMediso Holdings (Shenzhen) Limited, with the collaborative efforts of its international team and under the witness of authoritative experts, has announced a breakthrough in the key production technology for the medical isotope Ac-225 at a conference held in August, 2024,in London, UK. This core technology has been rigorously validated by a well-known research university in the UK, marking a significant milestone for PanMediso in the scale-up and commercial production of Ac-225. (Key members of the PanMediso Holdings’ international team at the Royal Academy of Engineering) PanMediso is a leading global enterprise in the research, production, and sale of medical isotopes Ac-225 and Ge-68. The company’s first phase focuses on addressing the technological and capacity bottlenecks associated with the long-term reliance on imported medical isotopes in China, aiming for realizing the full process flow of Ac-225 and Ge-68 in China. (PanMediso Holdings’ team meeting on the Technology Validation result) The company’s team comprises top experts in nuclear medicine from various countries, including fellows from the Royal Academy of Engineering and the Royal Society of London, a nuclear fuel expert from the UK government, the former chief scientist from a Canadian nuclear laboratory, and authoritative experts and professors from institutions such as Tsinghua University, Imperial College London, Hong Kong Polytechnic University, Shenzhen University, and Southwest Medical University. They are dedicated to research and clinical applications of radioactive isotopes and nuclear medicine. (PanMediso Holdings Team from left to right:Academician Robin Grimes, Chair of the Joint Technical Committee, Academician Andrew Carlick，CEO UK side, Mr. Leo Dang, CEO China side, Mr. Ivan Fu, Chairman of the Board of Directors) Ac-225 is considered one of the most promising therapeutic isotopes in clinical applications. Currently, dozens of Ac-225 drug pipelines are in clinical research stages worldwide, aiming for the treatment of various cancers including prostate cancer, neuroendocrine tumors, non-small cell lung cancer, breast cancer, and multiple solid tumors. Ac-225 has demonstrated excellent therapeutic effects in clinical research and treatment applications. It not only improves patient survival rates and treatment efficacy while reducing side effects but also lowers medical costs. As one of the most promising and highly anticipated medical isotopes, it is in high demand globally. However, only a few advanced teams outside China master the key production technologies for Ac-225, which involves a complex series of nuclear reactions and separation processes, resulting in a highly limited supply and severe long-term resource shortages. The increasing clinical research and treatment needs both domestically and internationally have exacerbated the shortage. PanMediso’s efforts to bridge this significant supply gap have garnered global attention and will effectively support further exploration of new cancer treatments. This dual value underscores PanMediso Holding’s great commitment to advancing global health through technological innovation and international collaboration, with a steadfast goal of contributing to the  community with a shared future of mankind. Academician Andrew Carlick, Co-Founder of PanMediso Holdings, snd Director & CEO on UK side, stated, “The cyclotron-based Ac-225 technology employed by PanMediso Holding is highly mature and has been validated by institutions. As the result of our years of wisdom and resources, it features the advantages such as high purity, high yield, low radiation, and minimal raw material loss, and will play a significant role in cancer treatment. With the combined efforts of our international team, we will continue to advance nuclear medicine technology.” Mr. Leo Dang, Co-Founder of PanMediso Holdings, snd Director & CEO on China side, commented, “PanMediso Holdings will continue to focus on technological and process innovations and plans to further expand the application fields of medical isotopes such as Ac-225 and Ge-68. We aim to provide a comprehensive solution from raw materials to finished products, from research to scaling, and to commercial-level production. We are building a complete technological platform for nuclear medicine, covering isotope production, core equipment research and development, nuclear drug RXO, next-gen diagnostic devices and AI+TAT. While intensifing our research and development strength for radiopharmaceuticals, we keep advancing the clinical translation and application of world-leading technologies, contributing PanMediso Holdings Power to scientific research and healthcare.” Contact Us Company: PanMediso Holdings (Shenzhen) Limited Contact: Claire Zhao Email: pchl@panmedisoholdings.com Website: http://panmedisoholdings.com

Latest News

五角大楼透露叙利亚袭击事件的损失

(SeaPRwire) -   美国指责伊朗对该国东北部的一个基地发动无人机袭击 五角大楼透露，在美国东北部的一处基地，8名美军士兵在无人机袭击中受伤。最初的袭击报道中没有提到人员伤亡。 据上周网上流传的视频显示，一架无人机可能在靠近土耳其和伊拉克边境的Rimelan基地引发了火灾。 美国国防部发言人、空军少将帕特里克·莱德周二向记者透露了伤亡人数。他说，8名伤者接受了“创伤性脑损伤”和吸入烟雾的治疗，其中3人已经重返工作岗位。 莱德表示，美国认为“伊朗支持的部队”发动了袭击，但五角大楼仍在努力确定可能参与袭击的具体民兵组织。 最初关于Rimelan无人机袭击的报道没有披露人员伤亡情况，但一名不愿透露姓名的美国官员上周五告诉路透社，医疗评估和损失评估正在进行中。 Rimelan，也被称为Rmelan和Rumalyn，位于叙利亚哈塞克省。2015年末，美军接管了阿布哈贾尔机场，并在那里建立了一个基地，被称为Rumalyn着陆区（RLZ）。该设施一直被用来为美军及其在打击伊斯兰国（IS，前称ISIS）恐怖分子方面支持的库尔德盟友提供物资。 2014年，IS占领了叙利亚和伊拉克的大部分地区。随着伊朗和俄罗斯支持叙利亚政府军对抗恐怖分子，美国派兵并招募库尔德民兵，以控制叙利亚东部，那里拥有该国大部分石油储备和农业用地。 尽管大马士革反对，并违反国际法，华盛顿此后一直在叙利亚保留了约900名士兵。五角大楼将其任务描述为“防止IS卷土重来”。与此同时，在美军支持下控制该地区的库尔德民兵拒绝重返叙利亚。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

ACN Newswire

AsiaMedic continues growth streak with 23% increase in revenue for First Half ended 30 June 2024

SINGAPORE, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - SGX Catalist-listed AsiaMedic Limited (the “Company” and together with its subsidiaries, the “Group”) announced its financial results for the financial period ended 30 June 2024 (“1H2024”).The Group’s 1H2024 revenue increased by S$2.4 million or 23% from S$10.7 million for 1H2023 to S$13.2 million due to the increase in revenue from the imaging and aesthetic businesses. The increase follows three consecutive years of revenue growth as the Group continues to pursue further capacity expansion to serve more patients.The increase in revenue from the diagnostic imaging business was primarily due to the addition of a third MRI scanner in the last quarter of 2023 while the increase in revenue from the aesthetics business was due to the engagement of a senior aesthetic doctor and the acquisition of the medical aesthetics business of LE Private Clinic in August 2023.The set-up of the new diagnostic imaging centre in Novena as well as expanded operations at Shaw Centre have necessitated the hiring of additional staff and doctors amidst intense competition for talent in the industry. The additional manpower was also supported by the purchase of new equipment incorporating the latest technology.The Group’s consumables expenses increased by 44% to S$1.0 million, personnel expenses increased by 30% to S$7.3 million, and laboratory and consultancy fees increased by 55% to S$2.2 million. In addition, depreciation of right-of-use assets increased by 36% to S$0.7 million for 1H2024 due to the purchase of the new MRI scanner in the last quarter of 2023 and the new CT scanner in 1H2024, as well as the lease of new clinic space at Orchard Building in 1H2023.As a result, the Group recorded a borderline loss of S$0.1 million for 1H2024 as compared to a profit of S$0.6 million for 1H2023. On the balance sheet, the Net Asset Value per share (cents) fell slightly by 0.04 cent from 1.18 cents per share to 1.14 cents per share.Investing for Future GrowthMr Arifin Kwek, Chief Executive Officer of AsiaMedic Limited, said, “We are encouraged by the continued revenue growth which reflects our ongoing pursuit of further capacity expansion to serve more patients. The Group’s new diagnostic imaging centre set-up in partnership with Sunway Berhad remains on track to commence operations by November 2024 and will nearly double the Group’s diagnostic imaging capacity.”“While our initial essential investments in new talent and technology may lead to margin compression in the short term, the expanded capacity and increase in productivity will also generate economies of scale and operational efficiencies which will play a significant role in the Group’s focus on attaining sustainable higher margins in the longer term,” he added.In August 2024, the Group implemented a new artificial intelligence virtual assistant to automate the scheduling of patient appointments. The system will free clinic staff from mundane tasks, allowing them to dedicate more time for high value in-person patient care.The Group’s focus on talent acquisition and investing in technology will pave the way for long-term sustainable growth and the creation of shareholder value.This press release should be read in conjunction with the financial statements announcement for 1H2024 uploaded on SGXNet.For media and analysts’ queries, please contact:Waterbrooks ConsultantsWayne KooT: (65) 9338 8166E: wayne.koo@waterbrooks.com.sgAbout AsiaMedic LimitedAsiaMedic Limited together with its subsidiaries (“AsiaMedic” or the “Group”) is a leading healthcare provider in Singapore which provides holistic solutions through integrated application of the latest medical technologies to prevent and detect early illnesses to achieve positive experiences and clinical outcomes for patients.The Group is committed to helping clients through practical and personalised solutions delivered with the highest professional standards of service and expertise in a timely, safe and consistent manner. Conveniently located at Orchard Road, AsiaMedic is a preferred one-stop centre for:Diagnostic imaging and radiology servicesMedical wellness and health screening servicesPrimary healthcare servicesMedical aesthetic services and productsFor more information, please visit www.asiamedic.com.sgThis announcement has been reviewed by the Company's Sponsor, Xandar Capital Pte Ltd. It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Ms Pauline Sim (Registered Professional) at 3 Shenton Way, #24-02 Shenton House, Singapore 068805. Telephone number: (65) 6319 4954. Copyright 2024 ACN Newswire via SeaPRwire.com.

ACN Newswire

Kincora Participation in the Sharewise Webinar

Melbourne, Australia--(ACN Newswire via SeaPRwire.com - August 14, 2024) - Kincora Copper Limited (ASX: KCC) (TSXV: KCC) (Kincora or the Company) is pleased to be participating in the Sharewise Webinar to be held today, Thursday August 15th, from 1:30pm Australian Eastern Standard Time (AEST).President & CEO Sam Spring will provide investors and shareholders an update on Kincora's asset portfolio, partner and corporate strategy outlining recent milestones, upcoming catalysts and with the opportunity for Q&A. A copy of the presentation is available at: https://images.newsfilecorp.com/files/2305/220005_664006_kincora_copper_participation_in_the_sharewise_webinar.pdfThis webinar can be viewed live via Zoom. Registration is free and available at:https://zoom.us/webinar/register/1917231614965/WN_3nN-VZ0lRpucefIyqLI2AAA recorded copy of the webinar will be made available following the event on Kincora's website (https://kincoracopper.com/interviews/ ) and Sharewise's YouTube (https://www.youtube.com/@sharewiseau ).This announcement has been authorised for release by the Board of Kincora Copper Limited (ARBN 645 457 763)About Kincora Copper LimitedKincora is dual listed on the ASX and TSX-V (ticker "KCC") and is an active explorer and project generator focused on world-class copper-gold discoveries. The company recently executed four agreements that unlock up to A$60 million in multiple year partner funding. Further new projects that offer a clear value path and targeted partnerships are proposed.Kincora's portfolio includes district scale landholdings and scalable drill-ready targets in both Australia and Mongolia's leading porphyry belts, the Macquarie Arc and Southern Gobi, respectively, and, the Company is targeting initial exposure to 10,000m of drilling in the next 6-month before ramping up to over 30,000 metres pa of drilling.For more information please visit Kincora's website at www.kincoracopper.com.For further information please contact: Sam Spring, President and Chief Executive Officersam.spring@kincoracopper.com or +61431 329 345Executive office400 - 837 West Hastings StreetVancouver, BC V6C 3N6, CanadaTel: 1.604.283.1722Fax: 1.888.241.5996Subsidiary office Australia Vista AustraliaLevel 4, 100 Albert RoadSouth Melbourne, Victoria 3205To view the source version of this press release, please visit https://www.newsfilecorp.com/release/220005 Copyright 2024 ACN Newswire via SeaPRwire.com.

ACN Newswire

Egyptian Heritage and Palestinian Folklore Shine at Alamein Festival

Egyptian Folk Traditions Take Centre Stage at AlameinIconic Performances Celebrate Egyptian and Palestinian HeritageOpera Al Layla Al-Kabira and Reda Troupe Steal the ShowAL ALAMEIN CITY, EGYPT, Aug 15, 2024 - (ACN Newswire via SeaPRwire.com) - The second edition of Alamein Festival 2024 celebrated Egypt's diverse cultural identity, heritage, and folk traditions.Part of the iconic performances throughout the festivalThe festival, organized by the United Media Services (UMS) under the patronage of Dr. Ahmed Hano, the Egyptian Minister of Culture, featured performances from folkloric groups across Egypt, highlighting the country's rich artistic and musical diversity.The Arab Opera troupe, led by Mohamed Mostafa, presented performances based on famous Egyptian songs, plays, and films, reinterpreted with new musical arrangements, along with a segment for children featuring beloved songs.The Ismailia troupe paid tribute to the Suez Canal region's folklore with performances like "The Saayaden" and "Betghani l meen ya hamam," underscoring Ismailia's cultural richness and significant contribution to the festival's diversity.Key performances included those by the "El-Horria" or Freedom and Aswan Folk Arts teams. The Aswan team, led by Medhat Mahram, performed Nubian folkloric pieces such as "Al-Arajeed" and "Al-Najrashad," with musical interludes by artists Hamada Harby and Omar Mustafa. With its rich historical and cultural significance, Aswan was a prominent and fitting feature of the festival.The Freedom team, under Nasreldin Mohamed, performed distinct pieces from Alexandria, including the "Banat Bahry" dance and the "Alexandrian Wedding Procession." These performances vividly brought Alexandria's rich cultural heritage to life.Additionally, the Assiut City Folk Arts team showcased traditional performances from the Assiut governorate, including "Al-'Asaayah," "Al-Tahmilah," and the "Arouset El-Mawlid" dance. These performances reflected Assiut's diverse historical influences, encompassing the Pharaonic, Roman, Coptic, and Islamic periods.A standout moment of the festival was the presentation of "Opera Al Layla Al-Kabira," a piece celebrating Egyptian visual identity by depicting Mawlid festivities. This operetta, composed by the late Salah Jahin with music by Sayed Mekkawy, remains a cultural cornerstone of Egyptian heritage.The iconic Reda Troupe also took part, performing a vibrant array of Egyptian folkloric dances. Their performance added to the celebration of the diverse heritage of various governorates, including "Dhaheya," and "Al-Hejala,"Palestinian folklore was also celebrated, with a concert featuring singer Mohamed Mounir and Dina El-Wedidi. El-Wedidi performed the operetta "Ragieen" and the iconic song "Leve Palestina," accompanied by a Palestinian dance troupe that showcased traditional performances in Palestinian costumes. This segment was a powerful celebration of the shared cultural heritage between Egypt and Palestine, making the festival a symbol of regional cultural unity.The 2024 edition of the New Alamein Festival featured a variety of activities, including theatrical performances produced by renowned producers and starring famous stars and young artists, football matches featuring legends and star players, visits from Egyptian ministers, the launch of major investment initiatives and partnerships, and collaboration with the United Media Services, the founder and organizer of Alamein Festival.For more information, please visit the festival website: https://elalameinfestival.comContact InformationEman Salempress@30n.orgSOURCE: Alamein Festival Copyright 2024 ACN Newswire via SeaPRwire.com.

ACN Newswire

Solar District Cooling Group Berhad Signs Underwriting Agreement with Mercury Securities Sdn Bhd for Its IPO on the ACE Market of Bursa Malaysia Securities Berhad

KUALA LUMPUR, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - Solar District Cooling Group Berhad ("SDCG") is pleased to announce that it has entered into an underwriting agreement with Mercury Securities Sdn Bhd (“Mercury Securities”) today for its upcoming initial public offering ("IPO") on the ACE Market of Bursa Malaysia Securities Berhad.1.Mr Chris Lai Ther Wei, Director, Head of Capital Markets, Mercury Securities 2.Ms Tan Tai Kim, Director, Corporate Finance, Mercury Securities 3.Mr Chew Sing Guan, Managing Director of Mercury Securities 4.Mr Edison Kong, Managing Director, Solar District Cooling Group 5.Ms Eileen Liuk, Executive Director, Solar District Cooling Group 6. Ms Sheryn Chow Suet Yim, Director, Corporate Finance, Mercury Securities [L-R]SDCG and its subsidiaries (“Group”) are principally involved in the provision and maintenance of building management systems (BMS), solar thermal solutions and energy saving services. The Group has a proven track record of enhancing energy efficiency across various sectors and strives to establish benchmarks in energy management and cost efficiency.The IPO involves the public issue of 118,670,000 new ordinary shares ("Issue Shares"), representing 28.00% of SDCG’s enlarged issued share capital of 423,822,460 ordinary shares upon its listing.The Issue Shares will be allocated in the following manner:Malaysian Public: 21,192,000 Issue Shares representing 5.00% of the enlarged issued share capital for application by the Malaysian public, with 50.00% set aside for Bumiputera investors.Eligible Persons: 21,192,000 Issue Shares representing 5.00% of the enlarged issued share capital for application by eligible directors, employees, and persons who have contributed to the Group’s success.Selected Investors: 76,286,000 Issue Shares representing 18.00% of the enlarged issued share capital made available by way of private placement to selected investors.Mercury Securities will underwrite all the 42,384,000 Issue Shares made available for application by the Malaysian public and eligible persons.Mr. Edison Kong, Managing Director of SDCG, expressed his enthusiasm for the IPO, stating, “Our listing will enhance our visibility and reputation in the market and enable our directors, employees, business partners, and public investors to participate in the growth and continued expansion of our business, increasing shareholder value. We would like to express our sincere gratitude to Mercury Securities for their support and confidence in our Group."He added, "This corporate milestone will help scale our Group to new heights by tapping new opportunities and responding to the evolving needs of our customers and market trends. We remain focused on providing innovative solutions that create value for our customers, striving to exceed their expectations.Mr. Chew Sing Guan, Managing Director of Mercury Securities said, "We are delighted to be the Principal Adviser, Sponsor, Sole Underwriter, and Sole Placement Agent for SDCG and to play a part in their new corporate journey as a listed company on the ACE Market of Bursa Malaysia Securities Berhad. The listing will enable SDCG to tap into the capital market for its growth and expansion plans in the future."1. Mr Chew Sing Guan, Managing Director of Mercury Securities 2. Mr Edison Kong, Managing Director, Solar District Cooling Group[L-R]ABOUT SOLAR DISTRICT COOLING GROUP BERHADSolar District Cooling Group Berhad (SDCG) and its subsidiaries (the “Group”) is an established services provider of energy-efficient building management and solar thermal systems in Malaysia. The Group specialises in the design, installation, and maintenance of BMS and solar thermal solutions, serving a diverse range of sectors including commercial, institutional, and industrial properties. With a commitment to sustainability and innovation, SDCG has earned a reputation for excellence in the building management system and solar thermal industries.For more information, visit www.sdc.myIssued By: Swan Consultancy Sdn Bhd on behalf of Solar District Cooling Group.For more information, please contact:Jazmin WanTel: +60 17-289 4110Email: j.wan@swanconsultancy.bizWilliam YeoTel: +60 16-213 2103Email: w.yeo@swanconsultancy.biz Copyright 2024 ACN Newswire via SeaPRwire.com.

Latest News

德国媒体：德国对 Nord Stream 爆炸案发出首个逮捕令

(SeaPRwire) -   据报道，嫌疑人被确定为乌克兰国民“弗拉基米尔·Z”。 据当地媒体报道，德国联邦检察官已针对北溪天然气管道破坏事件签发了第一份逮捕令。据信，嫌疑人是乌克兰公民，名为“弗拉基米尔·Z”。尚不清楚嫌疑人是否与基辅的军事或情报机构有关联。 迄今为止，尚无人声称对2022年9月在波罗的海发生的导致管道破裂的爆炸事件负责。由于破坏事件，俄罗斯向德国的天然气供应被迫中止。同样遭到破坏的北溪-2管道也从未投入运营，因欧盟官僚机构拖延而受阻。 德国国家广播公司ARD、南德意志报和时代报等媒体周三报道称，联邦检察官詹斯·罗梅尔于6月初签发了该案的第一份逮捕令。虽然据称已认定嫌疑人身份，但据报道，他的两名同胞，一对夫妇，被列为可能的同伙。 据报道，德国官员已向波兰同行提出合作请求，希望找到嫌疑人，据称他曾在华沙以西被追踪到，之后便消失无踪。 ARD报道称，它在周二设法通过电话联系到了嫌疑人，并补充说“弗拉基米尔·Z”坚持自己与破坏事件无关。 据国家广播公司称，据称破坏者乘坐一艘名为“仙女座”的游艇前往破坏地点。然而，波兰当局坚称，该船的航行“纯粹是观光性质”，船员显然没有被视为可疑人员。 ARD报道称，德国检察官对波兰的事件版本持怀疑态度。据称波兰官员也告诉德国同行，该游艇及其船员的监控录像已被删除。 ARD 声称，尽管有欧盟国家间条例，但华沙没有回应柏林关于弗拉基米尔·Z 可能下落的合作请求。 据德国媒体报道，调查人员尚未找到任何确凿证据将嫌疑人直接与乌克兰军方或情报机构联系起来。基辅的高级官员公开否认参与破坏北溪管道事件。 德国检察官办公室拒绝发表官方评论。 俄罗斯当局已将矛头指向美国，认为美国从破坏俄罗斯对德国的天然气供应中获益最多。莫斯科多次引用华盛顿在破坏管道之前公开表达的对北溪项目的担忧。 克里姆林宫还指责西方阻挠对爆炸事件的调查工作。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。